Wednesday, February 23, 2022 8:39:03 AM
They can soothe his nerves but cannot give him more info than what we get. If he becomes an active investor he can get the inside information. He knows when they are looking at funding well before we do because he is a funding source. But most of Wall Street does as well.
Based on the share price when above $1.50 I would assume he cashed in all his warrants. If he had a hint of delay of TLD he was making big money on warrant conversion and sale. I would guess he still holds in the millions of common shares. He was making 5 to 6 times his investment just by converting warrants and selling those shares. So he has made a great return even if the company goes bankrupt but still holds millions of shares for the climb up.
Bigger stepped in at the time when no one wanted to try. He is already rewarded big time. But when the vaccine sees approval he will be hailed as a genius. To claim he is a victim of delay is a bit rich. I could go for that kind of punishment.
Based on the share price when above $1.50 I would assume he cashed in all his warrants. If he had a hint of delay of TLD he was making big money on warrant conversion and sale. I would guess he still holds in the millions of common shares. He was making 5 to 6 times his investment just by converting warrants and selling those shares. So he has made a great return even if the company goes bankrupt but still holds millions of shares for the climb up.
Bigger stepped in at the time when no one wanted to try. He is already rewarded big time. But when the vaccine sees approval he will be hailed as a genius. To claim he is a victim of delay is a bit rich. I could go for that kind of punishment.
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
